ÂÜÀòÂÒÂ×

Vincent Forster is currently the CSO, Co-Founder & Board Member at Versantis. Prior to this, they were a Pioneer Fellow at ETH Zurich from November 2008 to March 2015, where they had a specific focus on drugs & biopharmaceuticals formulation and delivery. Vincent also worked as a Research Assistant at UC San Diego from July 2007 to August 2008, where they worked on cardiovascular bio-mechanics in collaboration with Medtronic Inc. and UCSD School of Medicine. Lastly, they were an IT Specialist at EPFL from August 2006 to August 2007, where they provided assistance for information network, internet security, backup services, and software support for EPFL collaborators.

Vincent Forster has a Ph.D. in Biopharmaceutics & Drug Formulation and Delivery from ETH Zürich, an M.Sc. in Bioengineering, Cardiovascular Biomechanics from UC San Diego, and an M.Sc. in Biomedical engineering from EPFL (École polytechnique fédérale de Lausanne). Vincent also has a B.Sc. in Life Sciences and Technology from EPFL (École polytechnique fédérale de Lausanne).

They work with Pamela Williamson - Acting Head of Regulatory Affairs, Kalman Wijaya - Head of Market Access, and Lise-Marie Füeg - Head of CMC. A direct report to Vincent Forster is and Désirée Füglistaller - R&D Project Lead. Vincent Forster reports to Mark J. Fitzpatrick, CEO & Board Member.